Niagen Bioscience, Inc. NAGE
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products
Chart by TradingView
5/9
Piotroski F — financial health
3.42
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $129.4M | $17.4M | $83.2M | — | $76.5M |
| 2024 | $99.6M | $8.6M | $61.6M | — | $46.1M |
| 2023 | $83.6M | -$4.9M | $50.8M | — | $28.5M |
| 2022 | $72.0M | -$16.5M | $42.8M | — | $28.7M |
| 2021 | $67.4M | -$27.1M | $41.5M | — | $31.7M |
| 2020 | $59.3M | -$19.9M | $35.3M | — | $16.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Fried Robert N | Chief Executive Officer | 2026-04-24 | Option exercise | 20,000 | $2.61 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.42 (safe)
- Working capital / assets 0.723
- Retained earnings / assets -1.546
- EBIT / assets 0.153
- Equity / liabilities 2.562
Source: SEC EDGAR filings · CIK 0001386570 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.